Identifying prognostic and predictive value of mutations associated with clinical outcomes in first line (1L) patients with advanced or metastatic non-small cell lung cancer (aNSCLC).

被引：0
|
作者：
Perez Parente, Diego
Cobo-Dols, Manuel
Hasan, Haroon
Olson, Sara
Pal, Navdeep
Wilkinson, Samantha
La Orden Tevar, Beatriz
Perez Fernandez, Mar
Provencio-Pulla, Mariano
机构：
[1] Roche Farma, Lung Canc Squad, Madrid, Spain
[2] Hosp Univ Reg Malaga, Malaga, Spain
[3] Genentech Inc, Product Dev Data Sci, San Francisco, CA USA
[4] Roche Prod Ltd, Welwyn Garden City, Herts, England
[5] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9047
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer
    Kazandjian, Dickran
    Gong, Yutao
    Keegan, Patricia
    Pazdur, Richard
    Blumenthal, Gideon M.
    JAMA ONCOLOGY, 2019, 5 (10) : 1481 - 1485
  • [42] Temporal Trends in Treatment Patterns for Advanced/Metastatic Non-Small Cell Lung Cancer (aNSCLC) in Routine Clinical Practice
    Stefaniak, V.
    Winfree, K.
    Cui, Z.
    Molife, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S669 - S669
  • [43] Next generation sequencing: a prognostic and predictive factor in advanced and metastatic non-small cell lung cancer
    Deneft, Josephine
    Descamps, Olivier
    Nockerman, Helene
    Catala, Gaetan
    de Lovinfosse, Solange
    ACTA CLINICA BELGICA, 2023, 78 : 12 - 13
  • [44] EGFR mutations in non-small cell lung cancer:: Predictive and prognostic implications
    不详
    CELLULAR ONCOLOGY, 2005, 27 (02) : 119 - 120
  • [45] KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer
    Martin, Petra
    Leighl, Natasha B.
    Tsao, Ming-Sound
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (05) : 530 - 542
  • [46] Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer†
    Byfield, Stacey DaCosta
    Chastek, Benjamin
    Korrer, Stephanie
    Horstman, Thomas
    Malin, Jennifer
    Newcomer, Lee
    CANCER INVESTIGATION, 2020, 38 (10) : 608 - 617
  • [47] LKB1 Mutations in Metastatic Non-Small Cell Lung Cancer (mNSCLC): Prognostic Value in the Real World
    Golozar, A.
    Collins, J.
    Fraeman, K.
    Nordstrom, B.
    Mcewen, R.
    Shire, N.
    Higgs, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S223 - S224
  • [48] CLINICAL OUTCOMES OF SECOND-LINE AND BEYOND (2L+) TREATMENTS (TXS) IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (aNSCLC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Voon, P. J.
    Di Maio, M.
    Coaquira, Castro J.
    Chaudhary, T.
    Finn, E.
    Xu, W.
    Zhan, L.
    VALUE IN HEALTH, 2024, 27 (06) : S36 - S36
  • [49] PREDICTIVE VALUE OF KRAS AND BRAF MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CHEMOTHERAPY
    Dingemans, Anne-Marie
    Smit, Egbert F.
    Heideman, Danielle
    Mellema, Wouter
    Derks, Jules
    Van, Robertjan Suylen
    Thunnissen, Erik
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1044 - S1044
  • [50] TREATMENT EFFECT MODIFICATION OF IMMUNOTHERAPY-BASED REGIMENS IN FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS (RCTS)
    Goring, S. M.
    Waser, N.
    Varol, N.
    Penrod, J. R.
    Yuan, Y.
    Wang, S.
    VALUE IN HEALTH, 2020, 23 : S29 - S29
12345